Lv2
110 积分 2025-03-05 加入
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
1个月前
已完结
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
3个月前
已完结
Pulmonary fibrosis: from pathogenesis to clinical decision-making
3个月前
已完结
Vitiligo: advances in pathophysiology research and treatment development
4个月前
已完结
Inhalable siRNA Targeting IL-11 Nanoparticles Significantly Inhibit Bleomycin-Induced Pulmonary Fibrosis
4个月前
已完结
Idiopathic pulmonary fibrosis
4个月前
已完结
Therapeutic Targeting of IL-11 for Chronic Lung Disease
4个月前
已完结
Chronic Spontaneous Urticaria: A Review
6个月前
已完结
皖公网安备34019202002308
